52 results about "Carbidopa" patented technology

The invention discloses a method for detecting the hydrazine content in a medicine containing carbidopa. The invention provides a method for detecting hydrazine content in a medicine containing carbidopa, which comprises the following steps: (1) mixing a sample to be detected and an aldehyde substance in a solvent under the action of acid, deriving hydrazine in the sample to be detected and the aldehyde substance to obtain a test solution, and (2) detecting the content of hydrazine in the test solution. Compared with the prior art, the method has the advantages that the carbidopa does not need to be removed through pretreatment, hydrazine introduced in the determination process can be ignored, operation is simple, derivatization time and sample injection time do not need to be accurately controlled, repeatability is good, and quantification is accurate.

The invention relates to the technical field of pharmacy, and discloses a carbidopa-levodopa sustained release tablet and a preparation method thereof.The carbidopa-levodopa sustained release tablet is prepared from, by mass, 65.4%-68.0% of levodopa, 17.0%-18.5% of carbidopa, 0.1%-0.5% of an adhesive, 0.1%-0.5% of a lubricant and 0.1%-0.5% of a coloring agent. And the mass percentage of the sustained-release material is 8.0%-9.0%. According to the carbidopa-levodopa sustained-release tablet and the preparation method thereof, polyvinyl acetate-crotonic acid copolymer is selected as a sustained-release material, hydroxypropyl cellulose is selected as an adhesive, the defects existing in the prior art are overcome, the carbidopa-levodopa sustained-release tablet can well control slow release of carbidopa and levodopa, and the sustained-release effect is good. According to the present invention, the release curve is highly consistent with the release curve of the original development agent, such that the safety and the effectiveness of the medication can be significantly improved, the wet granulation process is adopted, the addition mode of the adhesive is adjusted, the granulation process problem that the granulation is not easily performed when the active component content is large is solved, the preparation process is simple, and the industrial production is easy.

The invention provides an oral solid formulation comprising (a) a plurality of controlled release components comprising (i) a core comprising a mixture of levodopa and at least one pharmaceutically acceptable excipient, (ii) a controlled release coating surrounding the core, (iii) a muco-adhesive coating surrounding the controlled release coating and (iv) an enteric coating surrounding the muco-adhesive coating; and (b) one or more immediate release components comprising levodopa. The oral solid formulation also contains carbidopa and about 80% to 100% of the carbidopa in the oral solid formulation is present in the one or more immediate release components.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a carbidopa-levodopa pharmaceutical composition and a preparation method thereof.The carbidopa-levodopa pharmaceutical composition is composed of carbidopa, levodopa, a sustained-release material, an adhesive, a coloring agent and magnesium stearate, the sustained-release material is selected from one or a combination of two of hydroxypropyl cellulose MF and hydroxypropyl cellulose LF, and the adhesive is cellulose; in percentage by weight, the dosage of the slow-release material hydroxypropyl cellulose MF is 0.1-20.0%; and in percentage by weight, the dosage of the slow-release material hydroxypropyl cellulose LF is 0.1-20.0%. According to the carbidopa-levodopa sustained-release tablet disclosed by the invention, original and auxiliary bags in the prescription are accessible, the cost is low, the preparation process is simple and controllable, commercialized mass production can be realized, and the quality of the prepared product is consistent with that of the Ninning.

A method of treating and attenuating L-DOPA-induced dyskinesia, comprising administering an effective dose of at least one pharmacological agent, e.g., vilazodone, having serotonin-specific reuptake inhibition (SSRI) and serotonin receptor 1A (5-HT1AR) partial agonism activity, in conjunction with L-DOPA. Other agents, such as an L-DOPA decarboxylase inhibitor, e.g., carbidopa, or other adjunct treatments may also be provided.

The invention relates to the technical field of pharmaceutical analysis, in particular to a chromatographic method for determining optical isomers in a carbidopa raw material medicine and a preparation thereof by using an HPLC (High Performance Liquid Chromatography) method. The detection method is simple, convenient, rapid and accurate to operate, and specifically comprises the following steps: dissolving a proper amount of a sample with a solvent, diluting to a certain concentration, taking a certain volume of the sample, carrying out isocratic elution at a certain column temperature by adopting a high performance liquid chromatography, using a hand-type chromatographic column, a mobile phase A and a mobile phase B, and carrying out quantitative analysis by adopting a self-control method with correction factors. And calculating the isomer in the test solution. The method is good in specificity, solution stability, linearity, repeatability, intermediate precision and durability, and the detection result is accurate and reliable through verification.

A method for measuring the content of hydrazine in a carbidopa-containing drug, comprising the following steps: (1) in a solvent, under the action of acid, mixing a sample under test with an aldehydes substance, said sample being a carbidopa-containing drug, and hydrazine in said sample and the aldehydes substance being derivatized to obtain a test solution; and (2) measuring the content of the hydrazine in the test solution. Compared with the prior art, the method for measuring the content of hydrazine in a carbidopa-containing drug does not require pretreatment to remove carbidopa, introduces negligible hydrazine during measurement, is easy to operate, does not need to accurately control derivatization time and sample introduction time, and exhibits good repeatability and accurate measurements.

The invention discloses a multi-system drug release system for Parkinson's disease treatment, which is a capsule prepared from the following drug release systems and auxiliary materials in percentage by weight: 58.0 to 64.1 percent of an entacapone drug release system, 28.5 to 31.5 percent of a levodopa drug release system, 7.6 to 8.4 percent of a carbidopa drug release system and 0.5 to 1.5 percent of talcum powder, the drug-loaded pellet of the entacapone drug release system comprises a first pellet core, an isolation layer and an enteric layer which are sequentially arranged from inside to outside, and the drug-loaded pellet of the levodopa drug release system comprises a second pellet core and a first modification layer which are sequentially arranged from inside to outside, the drug-loaded pellet of the carbidopa drug release system comprises a third pellet core and a second modification layer which are sequentially arranged from inside to outside. The multi-system drug release system can realize independent and long-term slow release of three different active components without mutual interference. According to the method, a multi-system drug release system can be prepared with high loading capacity, and the problem of large dosage of drugs is effectively solved.

The present invention relates to the simultaneous use of L-tryptophan (L-Try) and L-5-hydroxytryptophan (5-HTP) and a peripheral degradation inhibitor for the prevention and therapy of pain, depression, sleeping disorders and other serotonin-dependent diseases or disorders of the CNS. All the components of the medicament are supposed to be released together. Carbidopa and / or benserazide are to be used as said peripheral degradation inhibitors for the tryptophan and the 5-hydroxytryptophan.

Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.

The invention relates to the technical field of biological medicine, and particularly discloses application of carbidopa in preparation of a medicine for treating melanoma. Carbidopa can target CD147 and has an inhibition effect on CD147, so that invasion, migration and growth of melanoma cells are inhibited, Carbidopa can be used for preparing drugs for treating melanoma, and new safe and effective drugs are provided for the field of melanoma treatment.

The present subject matter relates to a solid oral pharmaceutical composition comprising combination of levodopa and carbidopa as an active ingredient and dosage form comprises two types of components, the first components comprises immediate release component (IR component) and the second component comprises controlled release component (CR component).

The invention relates to a method for determining hydrazine in carbidobar by derivatization high performance liquid chromatography. Specifically, the invention relates to a method for quality control of Carbidopa as an anti-Parkinson disease drug, and especially relates to a method for determining trace impurity hydrazine in Carbidopa by using derivatization high performance liquid chromatography. In the method, octadecylsilane chemically bonded silica is used as a chromatographic column of a filling agent, and a test solution is prepared by the following steps: taking a to-be-detected test sample Carbidopa raw material medicine, putting the Carbidopa raw material medicine into a measuring flask, precisely adding water, shaking, immediately and precisely adding a diluent containing benzaldehyde and glacial acetic acid, shaking at proper time, immediately adding a proper amount of triethylamine, and uniformly stirring; and diluting to the scale by using a diluent, and uniformly shaking to obtain the test solution. The method provided by the invention can effectively and accurately determine the trace impurity hydrazine in the carbidopa bulk drug. The method provided by the invention has excellent methodological characteristics.

A method for measuring the content of hydrazine in a carbidopa-containing drug, comprising the following steps: (1) in a solvent, under the action of acid, mixing a sample under test with an aldehydes substance, said sample being a carbidopa-containing drug, and hydrazine in said sample and the aldehydes substance being derivatized to obtain a test solution; and (2) measuring the content of the hydrazine in the test solution. Compared with the prior art, the method for measuring the content of hydrazine in a carbidopa-containing drug does not require pretreatment to remove carbidopa, introduces negligible hydrazine during measurement, is easy to operate, does not need to accurately control derivatization time and sample introduction time, and exhibits good repeatability and accurate measurements.

Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.

The present disclosure provides a method for the treatment of Parkinson's disease comprising simultaneously or sequentially administering to a patient in need of treatment of Parkinson's disease a dosage form comprising(i) levodopa in an amount ranging from 50 mg to 300 mg,(ii) carbidopa in an amount ranging from 25 mg to 150 mg or a therapeutically equivalent amount of another aromatic amino acid decarboxylase inhibitor, and(iii) entacapone in an amount ranging from 50 mg to 300 mg, wherein the proportion of entacapone to carbidopa in said dosage form ranges from 0.3:1.0 to 3.2:1.0 by weight, a moderately potent COMT inhibitor in an amount ranging from 25 mg to 200 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.16:1.0 to 3.08:1.0 by weight, or a highly potent COMT inhibitor in an amount ranging from 1 mg to 100 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.006:1.0 to 1.54:1.0 by weight. Pharmaceutical dosage form used in said method are also disclosed.

The application belongs to the technical field of medicine, and particularly relates to a kind of opicapone oral disintegrating tablets and a preparation method thereof.The active component of the opicapone oral disintegrating tablet is opicapone, and the components are as follows according to weight percentage: opicapone 15-25%; filler 60-70%; glidant 1-4%; lubricant 1-4%; first disintegrating agent 2-6%; and second disintegrating agent 2-6%, wherein the first disintegrating agent and the second disintegrating agent are different, and preferably, the weight content of the opicapone is 15-20%.The opicapone oral disintegrating tablet of the application is suitable for the adjuvant therapy of levodopa / carbidopa, has a fast disintegration rate, stable product quality, does not need to be taken with water, and has strong patient compliance; in addition, the preparation process of the opicapone oral disintegrating tablet of the application is simple, has low cost, and is suitable for mass production.

The invention provides a carvolevodopa sustained-release capsule and a preparation method thereof. The carvolevodopa sustained-release capsule comprises a cured hollow soft capsule, and the cured hollow soft capsule is sequentially coated with a drug-containing layer and a thin film layer; the cured hollow soft capsule is obtained by curing a hollow soft capsule with a curing agent; the drug-containing layer comprises carbidopa, levodopa, a sustained-release material and an adhesive. The cardopa-levodopa sustained-release capsule provided by the invention has a unique gastric floating mechanism, has better gastric floating performance, and also has an in-vitro dissolution curve similar to that of a reference preparation. Meanwhile, raw materials and auxiliary materials are easy to obtain in the preparation process of the Carbidopa-levodopa sustained-release capsule, the preparation process is simple, the cost is low, and continuous and commercialized production is facilitated.

The present invention relates to a solid pharmaceutical composition manufactured by a wet granulation method comprising carbidopa and levodopa or pharmaceutically acceptable salts thereof, one or more disintegrant, one or more diluent, at least one binder, at least one lubricant, and one or more pharmaceutically acceptable excipients. The orodispersible tablet prepared using these excipients exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. Further, the present invention also relates to the process for preparing the said solid pharmaceutical composition.

The present invention relates to the simultaneous use of L-tryptophan (L-Try) and L-5-hydroxytryptophan (5-HTP) and peripheral degradation inhibitors for the prevention and therapy of pain, depression, sleep disorders and other serotonin-dependent diseases or disorders of the CNS. All components of the medicament are to be released together. Carbidopa and / or benserazide are to be used as the peripheral degradation inhibitors for tryptophan and 5-hydroxytryptophan.

Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.

The invention relates to the treatment of neurodegenerative diseases such as Parkinson patients with motor complications in need of Continuous Dopaminergic Stimulation. According to the invention a kit of pharmaceutical preparations is provided comprising levodopa and an AADC-inhibitor. Levodopa is applied via continuous subcutaneous infusion or by an oral modified release formulation and Continuous Dopaminergic Stimulation is achieved by almost complete inhibition of the peripheral levodopa metabolism. To reach far-going blockage of levodopa metabolism, an AADC-inhibitor (e.g., benserazide, carbidopa) is given orally in a much higher than normal dose and, as an indispensable prerequisite, the AADC-inhibitor has to be applied evenly distributed over the day. e.g., via a Modified Release formulation. In order to prevent levodopa conjugation over the COMT pathway, an oral COMT-inhibitor (e.g., opicapone) is also added. In addition, a drug-drug-interaction between the AADC-inhibitor and opicapone further increasing the activity of the former is likely to occur. The resulting effective inhibition of peripheral levodopa metabolism allows a marked reduction of the necessary (equivalent) levodopa (or prodrug) doses to 300-600 mg / day, which is, however, sufficient to reach high levodopa plasma levels of 1500 to 3000 ng / ml. The low daily levodopa dose is infused subcutaneously via minipump and is well-tolerated at the infusion site. Alternatively, the low daily levodopa dose is provided as an oral modified release formulation. The high steady-state levodopa plasma levels reached, allow effective Continuous Dopaminergic Stimulation-therapy for Parkinson's disease patients of any degree of severity. As additional benefit, the largely complete AADC-inhibition prevents the peripheral generation of dopamine and the cumbersome dopaminergic adverse effects (e.g., nausea, cardiovascular and gastro-intestinal adverse effects) are prevented.

The present disclosure relates to compositions of levodopa 4′-monophosphate and carbidopa 4′-monophosphate having a weight by weight ratio of about 20:1 and methods of treating Parkinson's disease and associated conditions by subcutaneous administration of such compositions.

To provide compositions for treating Parkinson's disease and associated conditions.SOLUTION: Pharmaceutical combinations and compositions comprise a carbidopa prodrug such as formula (I-a) and an L-dopa prodrug such as formula (II-a).SELECTED DRAWING: None

The application belongs to the technical field of pharmaceutical preparations, and specifically provides a carbidopa levodopa sustained-release tablet, which contains carbidopa, levodopa, potassium hydrogen tartrate, a sustained-release material, a binder and a lubricant. The carbidopa in the sustained-release tablet has good stability and is not prone to oxidative degradation, thereby improving the drug efficacy of the carbidopa levodopa sustained-release tablet. In addition, the wet granulation technology is used in the application, the preparation process is simple, the cost is low, and the application is suitable for industrial production.

The present disclosure provides (a) a pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent and (b) methods of treating Parkinson's disease and associated conditions comprising administering the pharmaceutical composition to a subject with Parkinson's disease.

The application relates to the technical field of medicines, and discloses a novel oral dissolving film which is composed of the following components in mass fractions: soluble polymer 38-48 parts, plasticizer 10-20 parts, filling agent 5-15 parts, solvent 20-30 parts, acid-base regulator 0.5-2 parts, sweetening agent 1-3 parts, and medicine or other active ingredients 5-25 parts; on the basis of the oral dissolving film, the application further provides a racemic carbidopa oral dissolving film which is composed of the following components in mass fractions: racemic carbidopa 45-55 parts, the above-mentioned oral dissolving film 40-50 parts, sweetening agent 1-3 parts, essence 0.5-2 parts, and other auxiliary materials 1-8 parts; the oral dissolving film has good solubility, accurate dosage, high drug loading, and the preparation method is simple and easy for industrialized production.

Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in a patient in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof.

An orodispersible solid pharmaceutical composition in tablet form is disclosed comprising a) carbidopa and levodopa or pharmaceutically acceptable salts thereof, b) one or more diluent, c) one or more

Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.